Is the price fair?
What AMGN's price assumes
Amgen trades at 24.4× earnings against 26.4× for the median Drug Manufacturers - General name, cheaper than its own group.
24.4
Trailing P/E · Drug Manufacturers - General median 26.4 · cheaper than the typical name in its group
- Price / sales
- 5.10
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.6%
Free cash flow yield · Drug Manufacturers - General median 5.7%
- Growth the price implies
- +4.2%
Growth the price implies · The price pays for +4.2% free cash flow growth a year for a decade; the business has delivered +1.7% a year over the last three.
Details›
- Price / book2026-Q1
- 20.7
- EV / EBIT2026-Q1
- 22.3
- EV / sales2026-Q1
- 6.32
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - General median P/E16 names
- 26.4
- Free cash flow, trailing twelve months
- $10.2B
- Market capitalisation
- $182.2B
- 3-year revenue growth
- +13%
- 3-year free cash flow growth
- +1.7%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $259.14 |
| Its own P/E history, median | $308.67 |
| Its own P/E history, upper quartile | $433.22 |
| 52-week range | $265.40 – $444.20 |
| Today | $393.22 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
The closest names by size in the same industry